Today’s Stock On Watch: Evoke Pharma Inc Stock Decline in Q2 2016 Driven by Institutional Investors

November 21, 2016 - By Winifred Garcia   ·   0 Comments

Today's Stock On Watch: Evoke Pharma Inc Stock Decline in  Q2 2016 Driven by Institutional Investors

Sentiment for Evoke Pharma Inc (NASDAQ:EVOK)

Evoke Pharma Inc (NASDAQ:EVOK) institutional sentiment decreased to 1.33 in Q2 2016. Its down -1.34, from 2.67 in 2016Q1. The ratio worsened, as 8 investment managers opened new or increased holdings, while 3 trimmed and sold holdings in Evoke Pharma Inc. The investment managers in our partner’s database now own: 1.01 million shares, up from 386,180 shares in 2016Q1. Also, the number of investment managers holding Evoke Pharma Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 2 Increased: 6 New Position: 2.

Evoke Pharma, Inc. is a specialty pharmaceutical company. The company has a market cap of $22.36 million. The Firm is focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. It currently has negative earnings. The Firm is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

It is down 65.50% since April 19, 2016 and is downtrending. It has underperformed by 69.36% the S&P500.

According to Zacks Investment Research, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company’s lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.”

Opaleye Management Inc. holds 2.95% of its portfolio in Evoke Pharma Inc for 695,000 shares. Knoll Capital Management Lp owns 55,660 shares or 0.12% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 2,887 shares. The New York-based Bank Of New York Mellon Corp has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 12,092 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 2 sales for $1.65 million net activity.

Evoke Pharma Inc (NASDAQ:EVOK) Ratings Coverage

Ratings analysis reveals 50% of Evoke Pharma’s analysts are positive. Out of 6 Wall Street analysts rating Evoke Pharma, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $2 while the high is $27. The stock’s average target of $14 is 686.52% above today’s ($1.78) share price. EVOK was included in 9 notes of analysts from August 20, 2015. The firm has “Buy” rating by Rodman & Renshaw given on Friday, October 2. The firm has “Buy” rating given on Thursday, August 20 by Brean Capital. H.C. Wainwright initiated the shares of EVOK in a report on Thursday, October 1 with “Buy” rating. The stock of Evoke Pharma Inc (NASDAQ:EVOK) has “Hold” rating given on Tuesday, July 19 by Noble Financial. The firm earned “Buy” rating on Monday, March 14 by Ascendiant Capital. The stock of Evoke Pharma Inc (NASDAQ:EVOK) earned “Hold” rating by Brean Capital on Monday, July 18. Northland Capital initiated the shares of EVOK in a report on Wednesday, March 16 with “Outperform” rating. On Monday, July 18 the stock rating was downgraded by Rodman & Renshaw to “Neutral”.

EVOK Company Profile

Evoke Pharma, Inc., incorporated on January 29, 2007, is a specialty pharmaceutical company. The Firm is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Firm is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration.

More notable recent Evoke Pharma Inc (NASDAQ:EVOK) news were published by: Marketwatch.com which released: “Evoke Pharma stock drops 76% after drug’s late-stage topline results miss …” on July 18, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on November 03, 2013, Seekingalpha.com published: “Evoke Pharma: Hop On And Ride The Elevator Higher” on July 31, 2016. More interesting news about Evoke Pharma Inc (NASDAQ:EVOK) were released by: 247Wallst.com and their article: “Is the FDA Changing Its Tune on Evoke Pharma?” published on September 07, 2016 as well as Globenewswire.com‘s news article titled: “Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for …” with publication date: July 26, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>